Newsquawk Logo

Bristol Myers Squibb (BMY) announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl (luspatercept-aamt) versus placebo for anemia in adults with Alpha (β)-Thalassemia.

Bristol Myers Squibb's positive results from their Phase 2 trial of Reblozyl for anemia in adults with Alpha-thalassemia mark a significant achievement, suggesting potential for increased market confidence in the drug's effectiveness.

Newsquawk StaffPublished On the live feed at — 4 more headlines followed before this page went public
Newsquawk headlinesUTC

Mexican GDP Growth Rate YoY Final (Q4) Y/Y 1.8% vs. Exp. 1.6% (Prev. -0.1%)

Mexican GDP Growth Rate QoQ Final (Q4) Q/Q 0.9% vs. Exp. 0.8% (Prev. -0.3%)

Bristol Myers Squibb (BMY) announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl (luspatercept-aamt) versus placebo for anemia in adults with Alpha (β)-Thalassemia.

Spain has mandated a new 30yr syndication

Slovenia's Treasury Director General says they expect to issue a Panda bond in 2026 in a CNY 2-4bln range, Econostream reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
  • "The non‑transfusion‑dependent (NTD) and transfusion‑dependent (TD) cohorts of the study met their respective primary endpoints, with Reblozyl demonstrating a statistically significant and clinically meaningful increase in hemoglobin levels in NTD patients with β‑thalassemia, and a statistically significant and clinically meaningful decrease in red blood cell (RBC) transfusion burden in TD patients with β‑thalassemia.
  • The study also met all key secondary endpoints. 
  • Safety findings were consistent with the known profile of Reblozyl in thalassemia.
Context

The met primary and secondary endpoints imply a strong outlook for future regulatory approval and could enhance the company's product pipeline, making it a key driver of stock performance in the pharmaceuticals sector.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.